Journals / Türk Kardiyoloji Derneği Arşivi / 2019 / Cilt: 47 - Sayı: 1

Safety of radial coronary angiography with uninterrupted direct-acting oral anticoagulant treatment

Oral antikoagülan tedavi kesilmeden yapılan radyal arter yoluyla koroner anjioyografi güvenliği

Pages
4–9
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The simple, uninterrupted DOACstrategy is comfortable, easy, and safe.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: It is not known whether direct-acting oral anticoagulants(DOACs), such as dabigatran, apixaban, and rivaroxabanincrease the risk of bleeding complications duringor after coronary catheterization.
📊
Key Findings & Data:The aim of this study was toinvestigate the safety of uninterrupted DOAC treatment duringdiagnostic radial coronary angiography (CAG).Methods: This study included 160 patients who underwentdiagnostic radial cardiac catheterization.
💡
Conclusion & Impact:The simple, uninterrupted DOACstrategy is comfortable, easy, and safe.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: It is not known whether direct-acting oral anticoagulants(DOACs), such as dabigatran, apixaban, and rivaroxabanincrease the risk of bleeding complications duringor after coronary catheterization. The aim of this study was toinvestigate the safety of uninterrupted DOAC treatment duringdiagnostic radial coronary angiography (CAG).Methods: This study included 160 patients who underwentdiagnostic radial cardiac catheterization. The 60 patients inthe group who were using a DOAC (apixaban, rivaroxaban, ordabigatran) were enrolled in a Group A. Post-procedure resultsfrom patients in Group A were compared with those of an ageandsex-matched control group (Group B) that included 100patients who underwent radial CAG who did not use a DOAC.Results: There was no significant difference in the procedureand compression times, creatinine level, or presence of hypertension,diabetes mellitus, smoking, alcohol use, vasculardisease, or congestive heart failure between the 2 groups.During the 1 -month follow-up period, only 1 radial occlusionwas registered in the control group (Group B). There was nocase of a large hematoma (>5 cm or extending to the forearm),dissection, fistula, perforation, or compartment syndrome.Hematomas smaller than 5 cm were seen in 2 patients(1 in each group). No thrombotic events were observed duringfollow-up examinations.Conclusion: Performing radial CAG with uninterruptedDOAC treatment appears to carry no risk of increased earlyor short-term complications. The simple, uninterrupted DOACstrategy is comfortable, easy, and safe.

Özet

Amaç: Dabigatran, apiksaban ve rivaroksabandan oluşan direkt etkili oral antikoagülanların (DOAK) koroner anjiyografi (KAG) sırasında ve sonrasında kanama riskini artırıp artırmadığı bilinmemektedir. Bu çalışmada DOAK tedavisine ara verilmeden yapılan KAG’nin güvenli olup olmadığı araştırıldı. Yöntemler: Çalışmamıza radyal arter yoluyla KAG yapılması kararlaştırılan toplam 160 hasta dahil edildi. Bu hastaların 60’ı DOAK (apiksaban, rivaroksaban ya da dabigatran) tedavisi almakta olup Grup A olarak adlandırıldı. Grup A’nin işlem sırasında ve sonrasındaki sonuçları yaş ve cinsiyet olarak eşleştirilmiş DOAK kullanmayan 100 hastadan oluşan kontrol grubuyla (Grup B) karşılaştırıldı. Bulgular: İşlem ve baskı süresi, kreatinin seviyesi, cinsiyet, hipertansiyon, diyabet, sigara ve/veya alkol kullanımı, damar hastalığı, kalp yetersizliği açısından iki grup arasında anlamlı fark saptanmadı. Bir aylık takip süresi boyunca, sadece kontrol grubundaki (Grup B) bir hastada radyal arter tıkanıklığı tespit edildi. Geniş hematom (>5 cm ya da ön kola uzanan hematom), diseksiyon, fistül, perforasyon ya da kompartman sendromuna rastlanmadı; 5 cm’den küçük hematom toplam iki hastada gözlendi (her iki gruptan birer hasta). İşlem sırasında ve takip süresince trombotik olay yaşanmadı. Sonuç: Direkt etkili oral antikoagülanlar tedavisine ara verilmeden radyal arter yoluyla yapılan KAG erken ya da kısa dönemde komplikasyon riskini artırmamaktadır. Basitçe uygulanan aralıksız DOAK tedavi stratejisi konforlu, kolay ve güvenlidir.

🔖

Cite This Article

Öz, T. K., Soylu, Ö., Gürol, T., Aydın, A., Dağdeviren, B., Sarıgül, N. U., ASLAN, U., Kobegenova, M. (2022). Safety of radial coronary angiography with uninterrupted direct-acting oral anticoagulant treatment. Türk Kardiyoloji Derneği Arşivi, Cilt: 47 - Sayı: 1, 4–9. https://ajindex.com/articles/632110

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467–507
  2. Spaulding J, Lefèvre T, Funk F, Thèbault B, Chauveau M, Ben Hamda K, et al. Left radial approach for coronary angiography: results of a prospective study. Cathet Cardiovasc Diagn 1996;39:365–70
  3. Pancholy SB. Comparison of the effect of intra-arterial versus intravenous heparin on radial artery occlusion after transradial catheterization. Am J Cardiol 2009;104:1083–5
  4. Hetherington SL, Adam Z, Morley R, De Belder MA, Hall JA, Muir DF, et al. Primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: changing patterns of vascular access, radial versus femoral artery. Heart 2009;95:1612–8
  5. Jolly SS, Yusuf S, Cairns J, Niemelä K, Xavier D, Widimsky P, et al; RIVAL trial group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised parallel group, multicentre trial. Lancet 2011;377:1409–20
  6. Hamon H, Mehta S, Steg PG, Faxon D, Kerkar P, Rupprecht HJ, et al. Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes. EuroIntervention 2011;7:91–7
  7. Rao SV, Ou FS, Wang TY, Roe MT, Brindis R, Rumsfeld JS, et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv 2008;1:379–86
  8. Jolly SS, Amlani S, Hamon M, Yusuf S, Mehta SR. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J 2009;157:132–40
  9. Agostoni P, Biondi-Zoccai GG, de Benedictis ML, Rigattieri S, Turri M, Anselmi M, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; Systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol 2004;44:349–56
  10. Tolosana J, Berne P, Mont L, Heras M, Berruezo A, Monteagudo J, et al. Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: Oral anticoagulation or bridging with intravenous hepar